Healthcare Equipment and Supplies
Company Overview of Oxford Immunotec Global PLC
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for the management of immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology. The company develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It offers T-SPOT.TB test used to test for tuberculosis. The company markets its T-SPOT.TB test through a direct sales force in the United State...
115D Innovation Drive
Abingdon, OX14 4RZ
Founded in 2002
Key Executives for Oxford Immunotec Global PLC
Chief Executive Officer & Executive Director
Total Annual Compensation: $370.4K
Chief Financial Officer
Total Annual Compensation: $300.0K
Chief Operations Officer
Total Annual Compensation: $293.5K
Chief Commercial Officer
Total Annual Compensation: $347.0K
Compensation as of Fiscal Year 2016.
Oxford Immunotec Global PLC Key Developments
Oxford Immunotec Global PLC Names Karen Koski as Head of Strategy and Investor Relations
Jun 5 17
Oxford Immunotec Global PLC announced the appointment of Karen Koski as Head of Strategy and Investor Relations. The newly created position will report directly to Oxford Immunotec's Chief Executive Officer, Dr. Peter Wrighton-Smith. Ms. Koski will join the company on June 21, 2017. Ms. Koski joins the company with a wealth of knowledge and experience in the diagnostics industry. Most recently, Ms. Koski served as a Director and Senior Equity Analyst at BTIG, LLC where she covered companies in the Medical Technology, Life Sciences, and Diagnostics sectors.
Oxford Immunotec Global plc Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017; Provides Revenue Guidance for the Second Quarter and Full Year of 2017
May 2 17
Oxford Immunotec Global PLC announced unaudited consolidated earnings results for the first quarter ended March 31, 2017. Revenue for the first quarter of 2017 was $21.5 million, representing 26% growth over the first quarter 2016 revenue of $17.1 million. On a constant currency basis, revenue growth was 27% versus the prior year period. Net loss for the first quarter of 2017 was $8.1 million, or $0.36 per share, compared to $7.0 million, or $0.32 per share, in the first quarter of 2016. LBITDA for the first quarter was $6.1 million compared to $6.4 million in the first quarter of 2016. Adjusted LBITDA was $7.1 million for the first quarter compared to $5.8 million in the same period in 2016. Loss from operations was $6.956 million against $7.194 million a year ago. Loss before income taxes was $8.025 million against $7.014 million a year ago.
The company expects to report revenue of between $24.9 and $25.7 million for the second quarter of 2017.
The company continues to expect to report full year 2017 revenue of between $102 and $105 million, representing 19% - 22% year-over-year growth. The company expects revenue to increase 21% to 24% for the year using constant exchange rates.
Oxford Immunotec Global PLC, Annual General Meeting, Jun 06, 2017
Apr 25 17
Oxford Immunotec Global PLC, Annual General Meeting, Jun 06, 2017, at 06:00 US Eastern Standard Time. Location: Milton Park Innovation Centre, Thames Room 99 Park Drive, Milton Park Abingdon, OX14 4RY United Kingdom Agenda: To elect class I directors; to ratify the audit committee's appointment of Ernst & Young LLP as U.K. Statutory auditor and U.S. independent registered public accounting firm for the fiscal year ending December 31, 2017; to re-appoint Ernst & Young LLP as U.K. statutory auditors; to authorize the audit committee to determine U.K. statutory auditors' remuneration for the fiscal year ending December 31, 2017; to receive the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2016; to receive and approve U.K. Statutory annual directors' remuneration report for the year ended December 31, 2016; to approve directors' remuneration policy; and to approve the amendment of the 2013 share incentive plan.
Similar Private Companies By Industry
Recent Private Companies Transactions